CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Glycopyrrolate (85 μg) +3 moredrug
Likely dose
Glycopyrrolate (85 μg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06545500
NCT06545500Phase 2Completed

A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA·interventional·Posted Aug 9, 2024·Updated Feb 9, 2026

In Brief

A Phase 2 clinical trial evaluating Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), and 2 other interventions for Chronic Obstructive Pulmonary Disease. Completed, enrolled 46 participants across 7 sites.

Detailed Summary

This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice daily via standard jet nebulizer over three 1-week active treatment periods and one 1-week placebo period in subjects with chronic obstructive pulmonary disease (COPD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedAug 9, 2024
Enrollment StartAug 16, 2024
Primary CompletionJan 2, 2025
Study CompletionJan 8, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 1.9 years ago

Interventions

Glycopyrrolate (85 μg)drug

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Glycopyrrolate (42.5 μg)drug

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Glycopyrrolate (14 μg)drug

Administered by a standard jet nebulizer, twice daily for 7 consecutive days

Placebodrug

Administered by a standard jet nebulizer, twice daily for 7 consecutive days